15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 了解,诊断和治疗乙型肝炎病毒感染的最新进展 ...
查看: 331|回复: 2
go

了解,诊断和治疗乙型肝炎病毒感染的最新进展

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

发表于 2020-9-22 12:06 |显示全部帖子
Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection
by Magda Rybicka * [OrcID] and Krzysztof Piotr Bielawski
Department of Molecular Diagnostics, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland
*
Author to whom correspondence should be addressed.
Microorganisms 2020, 8(9), 1416; https://doi.org/10.3390/microorganisms8091416
Received: 10 August 2020 / Revised: 8 September 2020 / Accepted: 11 September 2020 / Published: 15 September 2020
(This article belongs to the Special Issue Updates on HBV Infection)
Download PDF Browse Figure
Abstract
Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide and is associated with a broad range of clinical manifestations including cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Despite the availability of an effective vaccine HBV still causes nearly 900,000 deaths every year. Current treatment options keep HBV under control, but they do not offer a cure as they cannot completely clear HBV from infected hepatocytes. The recent development of reliable cell culture systems allowed for a better understanding of the host and viral mechanisms affecting HBV replication and persistence. Recent advances into the understanding of HBV biology, new potential diagnostic markers of hepatitis B infection, as well as novel antivirals targeting different steps in the HBV replication cycle are summarized in this review article.
Keywords: HBV; HBV RNA; HBcrAg; novel viral markers; direct-acting antivirals

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

发表于 2020-9-22 12:06 |显示全部帖子
了解,诊断和治疗乙型肝炎病毒感染的最新进展
作者:Magda Rybicka * [OrcID]和Krzysztof Piotr Bielawski
格但斯克大学和格但斯克医科大学生物技术学院分子诊断学系,波兰格但斯克Abrahama 58,80-307
*
应与之联系的作者。
微生物2020,8(9),1416; https://doi.org/10.3390/microorganisms8091416
收到:2020年8月10日/修订:2020年9月8日/接受:2020年9月11日/发布:2020年9月15日
(本文属于有关HBV感染的特刊)
下载PDF浏览图
抽象
慢性乙型肝炎病毒(HBV)感染影响全球2.92亿人,并与多种临床表现相关,包括肝硬化,肝衰竭和肝细胞癌(HCC)。尽管可获得有效的疫苗,HBV每年仍导致近900,000例死亡。当前的治疗方法可以控制HBV,但是由于无法从感染的肝细胞中完全清除HBV,因此无法治愈。可靠细胞培养系统的最新发展使人们能够更好地了解影响HBV复制和持久性的宿主和病毒机制。这篇综述总结了对HBV生物学认识的最新进展,新的潜在的乙型肝炎感染诊断标志物以及针对HBV复制周期中不同步骤的新型抗病毒药。
关键字:HBV; HBV RNA; HBcrAg;新型病毒标记物;直接作用抗病毒药

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

发表于 2020-9-22 12:07 |显示全部帖子
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-4-18 08:55 , Processed in 0.013930 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.